Table 5.
Relative risk of clinical risk factors and outcomes
| Risk factor | Clinical outcome | Relative risk | P‐value | |
|---|---|---|---|---|
| Yes | No | |||
| Oxygen supplementation, n (%) | ||||
| n | 39 | 64 | ||
| Male gender | 24 (62) | 31 (48) | 1.4 | 0.23 |
| Hypertension | 20 (51) | 17 (27) | 1.9 | 0.02 |
| ACE/ARB use | 19 (49) | 14 (22) | 2.0 | 0.01 |
| Cardiovascular disease | 11 (28) | 5 (8) | 2.1 | 0.01 |
| Respiratory disease | 9 (23) | 10 (16) | 1.3 | 0.43 |
| Diabetes | 9 (23) | 5 (8) | 1.9 | 0.04 |
| Immunosuppression | 4 (10) | 2 (3) | 1.9 | 0.20 |
| ICU admission, n (%) | ||||
| n | 18 | 85 | ||
| Male gender | 14 (78) | 41 (48) | 3.1 | 0.04 |
| Hypertension | 11 (61) | 26 (31) | 2.8 | 0.03 |
| ACE/ARB use | 10 (56) | 23 (27) | 2.7 | 0.03 |
| Cardiovascular disease | 6 (33) | 10 (12) | 2.7 | 0.03 |
| Respiratory disease | 5 (28) | 14 (16) | 1.7 | 0.32 |
| Diabetes | 6 (33) | 8 (9) | 3.2 | 0.02 |
| Immunosuppression | 1 (6) | 5 (6) | 0.95 | 1 |
| Death, n (%) | ||||
| n | 4 | 99 | ||
| Male gender | 3 (75) | 52 (53) | 2.6 | 0.62 |
| Hypertension | 4 (100) | 32 (32) | NA | 0.01 |
| ACE/ARB use | 4 (100) | 29 (29) | NA | 0.01 |
| Cardiovascular disease | 3 (75) | 13 (13) | 16.3 | 0.01 |
| Respiratory disease | 1 (25) | 18 (18) | 1.5 | 0.56 |
| Diabetes | 3 (75) | 9 (9) | 19 | <0.01 |
| Immunosuppression | 0 | 6 (6) | 0 | 1 |
P‐values calculated with Fisher's exact test.
ACE, angiotensin‐converting enzyme; ARB, angiotensin receptor blocker.